We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Endoscopic Treatment Could Spare Surgery in Barrett's Esophagus Patients

By HospiMedica International staff writers
Posted on 02 Mar 2010
A new study has found that early tumor formation in Barrett''s esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions.

Researchers from the University of Amsterdam (UVA; The Netherlands), Evangelisches Krankenhaus (Düsseldorf, Germany), and Erasme University Hospital (Brussels, Belgium) conducted a multicenter, prospective cohort study that included 24 patients (mean age 65), with BE less or equal to 12 cm containing high-grade intraepithelial neoplasia (HGIN) or early cancer.

Visible lesions were endoscopically resected, followed by serial RFA; focal escape endoscopic resection was used if Barrett tissue persisted despite RFA. More...
Complete response, defined as all biopsies negative for intestinal metaplasia and neoplasia, and was assessed during endoscopy with four-quadrant biopsies taken for every one centimeter of the original Barrett's segment, two months after the patient was last treated.

The results showed that of the 23 patients that underwent pre-RFA endoscopic resection for visible lesions, 16 patients had early cancer and seven patients had HGIN. The worst residual histology results, pre-RFA (and after any endoscopic resection) were HGIN (10 patients), low-grade intraepithelial neoplasia (11 patients), and intestinal metaplasia (three patients). Neoplasia and intestinal metaplasia were eradicated in 95% and 88% of patients, respectively; after escape endoscopic resection in two of the patients, rates improved to 100% and 96%, respectively. After additional follow-up for a median period of 22 months, no neoplasia had recurred. The study was published in the January 2010 issue of the journal Clinical Gastroenterology and Hepatology.

"Combining endoscopic resection with complete removal of residual Barrett cells with radiofrequency ablation may decrease the recurrence of lesion formation, and could potentially limit the number of Barrett's esophagus cases that progress to esophageal cancer,” said lead author Jacques Bergman, M.D., of the Academic Medical Center at UVA.

Currently, the cornerstone of treatment of early BE tumors are endoscopic resection in which visible lesions are removed, and tumor infiltration depth and differentiation are assessed. After focal endoscopic resection, however, the residual Barrett mucosa remains at risk for malignant transformation and cancer recurrences are found in 30% of patients during follow-up. To prevent such lesions, newer endoscopic approaches, including RFA, have been studied in an attempt to eradicate the residual Barrett mucosa.

Related Links:

University of Amsterdam
Evangelisches Krankenhaus
Erasme University Hospital



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical System
Stealth AXiS
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.